Clinical Trial Search

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque…

Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio

Primary: Number of Participants With One or More Drug-related Adverse Events — 42; 38; 11; 9 participants

Primary: Change From Baseline in Height Velocity at Month 6 Using Last Observation Carried Forward (LOCF) Method — 5.63; 4.94; 4.45; 1.01 centimeter/year (cm/yr) — p=<0.0001

Primary: Safety: Number of Participants With Serious and Specific Adverse Events — 50; 57; 42; 22 participants

Primary: Intragastric pH Time Course Over 24 Hours — 10.63; 10.63; 8.90; 8.90 percentage of time

Primary: Change From Baseline in Visual Analog Scale of Pain Intensity (VASPI) at 60 Minutes Post Dose — 47.3; 44.1 units on a scale — p=0.211

Primary: Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death — 189; 12; 0 participants

Primary: Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina — 399; 406 participants — p=0.8542

Primary: Change in HbA1c From Baseline to Week 24 — -0.65; -0.74 Percentage of hemoglobin — p=0.2664

Primary: Absolute Change in HbA1c From Baseline to Week 24 — -0.57; 0.06 percentage of hemoglobin — p=< 0.0001

Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.47; -0.83 percentage of hemoglobin — p=0.0004

Primary: Progression Free Survival (Independent Assessment) — 9.0; 11.1 months — p=0.0731

Primary: Number of Participants With at Least One Serious Adverse Event (SAE) — 4; 19 participants